Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($0.87), $0.14 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $15.97 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.